News | March 03, 2024
Briefs: SMS Pharmaceuticals and Vimta Labs
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
With this, the company can start selling Ibuprofen in the European markets.
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)